An exploratory observational study of clinical significance of PK/PD (pharmacokinetic/pharmacodynamic) concentration after opioid to patients with urological cancer pain

An exploratory observational study of clinical significance of PK/PD (pharmacokinetic/pharmacodynamic) concentration after opioid to patients with urological cancer pain - The investigation of (pharmacokinetic/pharmacodynamic) of opioid

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035523

Enrollment

Registered

2019-01-11

Start date

2019-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients using opioids for urological cancer pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients using opioid analgesics. 2)Patient who agreed. 3)Patient whose pain is controlled.The number of times of rescue drug use is up to 4 times a day. 4)Patient who can communicate.

Exclusion criteria

Exclusion criteria: 1)patients who had allergy in oxycodone. 2)patients who had allergy in Fentanyl. 3)patients who had allergy in Tapentadol. 4)patients who had allergy in morphine. 5)patients who had allergy in Hydromorphone. 6)patients who had allergy in methadone. 7)patients including severe adverse event. 8)pregnant patients/patients giving lactation 9)Patient with difficult blood sampling 10)unadequate patients

Design outcomes

Primary

Measure	Time frame
Correlation between changes in opioid blood levels and changes in pain	—

Countries

Japan

Contacts

Public Contactyosuke sugiyama

Nagoya City University Graduate School of Medical Sciences Department of Clinical Pharmaceutics

phsugi@med.nagoya-cu.ac.jp052-851-5511

Outcome results